Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Aldeyra Therapeutics for its New Drug Application of reproxalap for the treatment of dry eye dis ...

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

A new interpretation of a 3,500-year-old medical text from Egypt suggests that ancient physicians might have bathed patients' eyeballs in human breast milk to treat certain ophthalmic conditions. And ...

From the labs of Galway to the research hubs of Dublin and Cork, a new generation of start-ups is transforming how we diagnose, treat and manage health conditions.

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

March 17 (Reuters) - The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said on Tuesday, sending its shares down 65% in ...